Ligand-Directed Nanobialys as Theranostic Agent for Drug Delivery and Manganese-Based Magnetic Resonance Imaging of Vascular Targets

Abstract

Noninvasive magnetic resonance (MR) molecular imaging and targeted drug delivery systems, often referred to as theranostic agents, are being developed to enable improved detection, patient risk stratification, site-specific treatment, and longitudinal monitoring. 1 One example of these agents, a gadolinium-based perfluoro-carbon nanoparticle, has been used to detect, characterize, treat, and follow angiogenesis in preclinical models of cancer and atherosclerosis. Despite the preclinical success of this and related nanotechnology platforms, the recent discovery of nephrogenic systemic fibrosis (NSF), a serious and unexpected side effect of gadolinium blood pool agents observed in some patients with renal disease or following liver transplant, has cast a shadow on currently approved MR contrast agents. 2 Patients with NSF develop thickening of the skin and connective tissues that can inhibit arm and leg movements and even lead to bone fractures. Approximately 5% of patients experience a rapidly progressive course, which may result in death due to widespread fibrosis. The cause of NSF is unknown and there is no effective treatment of this condition. Although gadolinium has been the dominant paramagnetic metal for MR contrast agents, the issue of NSF has induced consideration of alternative approaches.Manganese was one of the first reported examples 3,4 of paramagnetic contrast material studied in cardiac and hepatic MRI because of its efficient R 1 enhancement. Similar to Ca 2+ and unlike the lanthanides, manganese is a natural cellular constituent, and often a cofactor for enzymes and receptors. Manganese blood pool agents, such as mangafodipir trisodium, have been approved as a hepatocyte-specific contrast agent with transient side-effects due to dechelation of manganese from the linear chelate. Nontargeted liposomal agents have included MnSO 4 3c or Mn-DTPA. 3d Release of Mn caused by disruption of the vesicles allowed MR detection of sites where the vesicles were non-specifically entrapped.Manganese(III)-labeled nanobialys (1) are a potential targeted MR theranostic nanoparticle produced by molecular self-assembly of amphiphilic branched polyethylenimine, which has a toroidal shape, tunable particle size, and low polydispersity. The "bialy" shape affords increased stability and presents kinetically stable, porphyrin coupled Mn(III) complexes directly to the surrounding water. In a typical synthesis, commercially available branched polyethylenimines (MW = 10 kDa) are hydrophobically modified (nominal 55% conjugation of the 1° amine) with linoleic acid by activating the carboxylic acid groups with 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (1.2 equiv) and allowing the reaction overnight at ambient temperature. Supramolecular self-assembly of the amphiphilic polymer in anhydrous chloroform, assumes inverted micellar 5 structures (2) that are able to transfer a water soluble new candidate contrast agent Mn(III)-protoporphyrin chloride (Mn-PPC, 4) into chloroform. Synergistic self-assembly of the ag...

Preparation and characterization of gadolinium-loaded PLGA particles surface modified with RGDS for the detection of thrombus

“…These results suggest that thrombus targeted PLGA particles can be bound to the surface of the thrombus and imaged using a clinical MR scanner. Previous reports 5,6,30 have demonstrated the same findings using other thrombus targeted MR probes. The MR findings are supported by the analysis of the pathological frozen sections in our study.…”

“…To date, numerous studies have been focused on the design of MR probes with high relaxation efficiency to improve MR thrombus depiction. [4][5][6][7][8][9] However, such probes are becoming more and more complicated, are not readily available for other researchers, and are not yet approved for clinical applications. In this study, we introduce a relatively simple method to prepare an MR probe for targeting activated platelets.…”

“…Poly (lactic-co-glycolic acid) (PLGA) has attracted considerable attention due to its attractive properties: (1) it is biodegradable and biocompatible, (2) the US Food and Drug Administration and European Medicine Agency have approved it for use in drug delivery systems for parenteral administration, (3) it has well described formulations and methods of production adapted to various types of drugs, eg, hydrophilic or hydrophobic small molecules or macromolecules, (4) it protects drugs from degradation, (5) it has the possibility of sustained release, (6) the surface properties can be modified to provide better interaction with biological materials, and (7) it can possibly target particles to specific organs or cells. 10,11 PLGA is widely used for the preparation of intravenous drug delivery systems and biomimetic materials and has extensive application prospects in drug delivery, disease diagnosis, treatment, medical imaging, and tissue engineering.…”

Polymer beacons for luminescence and magnetic resonance imaging of DNA delivery

“…Considering that the delivery vehicle has a central role in the mechanisms, kinetics, efficacy, and toxicity of nucleic acid medicines, little is known about how the vehicle structure affects drug fate both in vitro and in vivo. For this reason, smart biomaterials termed ''theranostic'' agents are being developed that provide diagnostic imaging, therapeutic delivery, and the ability to monitor treatment efficacy (9). Indeed, the parallel development of novel nucleic acid drugs and theranostic vehicles that offer disease diagnosis, treatment, and the ability to understand the delivery mechanisms/kinetics on a range of biological scales will advance this field toward the discovery of personalized treatment strategies.…”

Interventional oncology: the future

“…When given systemically, 80% of the drug may be selectively retained by the tumor cell or tissue. If labeled with manganese (Mn [III]), these agents can be imaged by magnetic resonance imaging as it reaches its tumor target [4]. Theranostic agents may involve the diagnostic pediatric radiologist in the future as the evaluator of IO agent delivery.…”